Two Sigma Investments LP Sells 105,671 Shares of Immunic, Inc. (NASDAQ:IMUX)

Two Sigma Investments LP lessened its holdings in Immunic, Inc. (NASDAQ:IMUX) by 40.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 157,204 shares of the company’s stock after selling 105,671 shares during the quarter. Two Sigma Investments LP owned 0.17% of Immunic worth $157,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of IMUX. Invesco Ltd. purchased a new stake in Immunic during the fourth quarter worth about $37,000. Barclays PLC bought a new position in shares of Immunic during the 4th quarter valued at approximately $84,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Immunic by 90.0% during the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 204,579 shares of the company’s stock valued at $205,000 after acquiring an additional 96,894 shares during the period. Bridgeway Capital Management LLC increased its stake in shares of Immunic by 11.5% during the 4th quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company’s stock worth $215,000 after purchasing an additional 22,200 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of Immunic by 45.6% in the 4th quarter. Renaissance Technologies LLC now owns 566,623 shares of the company’s stock worth $567,000 after purchasing an additional 177,542 shares during the period. Institutional investors own 51.82% of the company’s stock.

Immunic Stock Performance

Shares of IMUX opened at $0.84 on Friday. Immunic, Inc. has a 52-week low of $0.56 and a 52-week high of $2.11. The stock’s 50-day simple moving average is $0.95 and its 200 day simple moving average is $1.04. The stock has a market capitalization of $80.86 million, a price-to-earnings ratio of -0.69 and a beta of 1.48.

Immunic (NASDAQ:IMUX) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.25) earnings per share for the quarter, meeting the consensus estimate of ($0.25). On average, research analysts forecast that Immunic, Inc. will post -0.94 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. William Blair reiterated an “outperform” rating on shares of Immunic in a research note on Friday, May 16th. B. Riley restated a “buy” rating and issued a $5.00 target price (down from $6.00) on shares of Immunic in a research note on Friday, May 23rd. D. Boral Capital reiterated a “buy” rating and set a $10.00 price target on shares of Immunic in a research note on Thursday, June 5th. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Immunic in a report on Thursday, May 1st. Finally, Wall Street Zen downgraded shares of Immunic from a “hold” rating to a “sell” rating in a report on Thursday, March 20th. One research analyst has rated the stock with a sell rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Immunic has a consensus rating of “Buy” and an average target price of $11.60.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.